boothcheck doesn't label ADMA overvalued or undervalued and publishes no house fair value, target price, or buy/sell rating. Individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. In the published model solve dated 2026-09-07T04:18:58.441Z, anchored at $9.58, ADMA is priced for growth of +4.2%. The price is supported by asset-based and relative-multiple and growth-DCF value, while earnings-power lands below the price. A value/asset-supported name, not a pure growth bet. The report narrative was composed 2026-07-25. The more the price assumes beyond what ADMA BIOLOGICS, INC. has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.
Derived from ADMA BIOLOGICS, INC.'s SEC EDGAR filings via a reverse-DCF inversion. Last analyzed July 25, 2026.
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.